In February 2026, Blue Cross Blue Shield of Michigan announced a policy that got the attention of every procedural specialty in the country: a 50% reimbursement reduction for non-preventive E/M services (codes 99202-99205 and 99212-99215) billed with Modifier 25 on the same day as a minor procedure with a 0- or 10-day global period.
Then, on April 15, 2026, after coordinated pushback from the Michigan State Medical Society, the American Osteopathic Association, and more than two dozen specialty organizations, BCBSM paused implementation with no revised effective date announced.
If your takeaway is “crisis averted,” we’d encourage you to read that timeline again. A major Blues plan formally proposed cutting same-day E/M reimbursement in half, defended the policy through two months of organized opposition, and paused it without withdrawing it. That’s not a policy dying. That’s a policy waiting.
Modifier 25 tells a payer that a provider performed a significant, separately identifiable E/M service on the same day as a procedure. Think of a joint injection plus a genuine evaluation, or a lesion removal plus a new-problem workup. Used correctly, it’s how practices get paid for real work.
Used loosely, it’s a compliance liability. Payers and federal regulators have flagged Modifier 25 overuse for years; in one widely cited case reported by Becker’s, a Florida physician group paid $1.7 million to settle federal allegations of Modifier 25 misuse. From a payer’s perspective, same-day E/M claims are a rich audit target: high volume, historically paid without question, and frequently supported by documentation that doesn’t explicitly establish the “above and beyond” nature of the visit.
Whether or not BCBSM’s cut ever takes effect, the announcement itself signals where payer scrutiny is heading. Practices that bill same-day E/M and procedures at high volume should expect:
The highest-risk claims are the ones most practices worry about least: clean, high-volume, consistently paid encounters concentrated among productive providers. Those are exactly the claims traditional workflows never re-examine, and exactly where an audit hits hardest.
The pause is a gift of time. Here’s how to use it:
Audit your own Modifier 25 utilization. Know your same-day E/M billing rate by provider and compare it against specialty norms. Outliers get audited first.
Pressure-test your documentation. For a sample of paid Modifier 25 claims, ask one question: does the note independently justify the E/M as separate and significant? If a payer auditor read it cold, would it hold?
Quantify your exposure. Model what a 50% same-day E/M reduction, or a recoupment on 12 months of claims, would mean for your revenue by payer. You can’t manage a risk you haven’t measured.
Watch the policy landscape. BCBSM has committed only to a pause. When a new effective date is announced, practices will need lead time to adjust workflows.
Pollux clients don’t wait for the audit letter. Our revenue intelligence approach identifies Modifier 25 risk before claims are submitted, flags documentation gaps that trigger payer review, and quantifies financial exposure across payers and providers. You know which encounters are exposed, which dollars are at risk, and which claims are defensible.
That’s the difference between compliance and revenue protection.
Want to know your practice’s Modifier 25 exposure before a payer calculates it for you? Schedule a discovery call or book a free audit.
